Andexanet alfa for the reversal of factor Xa inhibitors-Reference-Cited by-同舟云学术

Andexanet alfa for the reversal of factor Xa inhibitors

Published:2019-04-11 Issue:5 Volume:19 Page:387-397
ISSN:1471-2598
Container-title:Expert Opinion on Biological Therapy
language:en
Short-container-title:Expert Opinion on Biological Therapy

Author:

Favresse J¹,Hardy M²,van Dievoet MA³,Sennesael AL⁴,Douxfils J⁴⁵^ORCID,Samama CM⁶,Vornicu O²,Dincq AS²,Lessire S²,Mullier F¹^ORCID

Affiliation:

1. Namur Thrombosis and Haemostasis Center, Hematology Laboratory, Université catholique de Louvain, CHU UCL Namur, Yvoir, Belgium

2. Department of Anesthesiology, CHU UCL Namur, Namur Thrombosis and Haemostasis Center, Université Catholique de Louvain, Yvoir, Belgium

3. St-Luc University Hospital and Catholic University of Louvain, Department of Laboratory Medicine, Hematology Laboratory, Brussels, Belgium

4. Department of Pharmacy, Namur Thrombosis and Haemostasis Center, Namur Research Institute for Life Sciences, Namur, Belgium

5. Qualiblood s.a., Namur, Belgium

6. Department of Anaesthesiology and Intensive Care Medicine, Cochin University Hospital, Paris Descartes University, Paris, France

Funder

not funded

Publisher

Informa UK Limited

Subject

Clinical Biochemistry,Drug Discovery,Pharmacology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14712598.2019.1599355

Reference99 articles.

1. European Medicines Agency Lixiana - Summary of Product Characteristics 2018. (updated 2018/10/08, accessed on 2018/12/31) Available from: https://www.ema.europa.eu/documents/product-information/lixiana-epar-product-information_en.pdf.

2. European Medicines Agency Pradaxa - Summary of Product Characteristics 2018. (updated 2018/06/15, accessed on 2018/12/31). Available from: https://www.ema.europa.eu/documents/product-information/pradaxa-epar-product-information_en.pdf.

3. European Medicines Agency Xarelto - Summary of Product Characteristics 2018. (updated 2018/09/06, accessed on 2018/12/31). Available from: https://www.ema.europa.eu/documents/product-information/xarelto-epar-product-information_en.pdf.

4. European Medicines Agency Eliquis - Summary of Product Characteristics 2018. (updated 2018/09/03, accessed on 2018/12/31). Available from: https://www.ema.europa.eu/documents/product-information/eliquis-epar-product-information_en.pdf.

5. National Trends in Ambulatory Oral Anticoagulant Use

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Use of Andexanet Alfa for Factor Xa Inhibitor Reversal in US Verified Trauma Centers: A National Survey;Clinical and Applied Thrombosis/Hemostasis;2024-01

2. Reperfusion therapy of ischaemic strokes in oral anticoagulated patients: an expanding field in clinical practice;Neurologia i Neurochirurgia Polska;2023-12-29

3. The methods for removal of direct oral anticoagulants and heparins to improve the monitoring of hemostasis: a narrative literature review;Thrombosis Journal;2023-05-19

4. Andexanet Alfa to Reverse the Effect of Factor Xa Inhibitors in Intracranial Hemorrhage;CNS Drugs;2023-05-03

5. Dental Implant Surgery for Patients Receiving Non-vitamin K Antagonist Oral Anticoagulants (NOACs); Clinical Considerations and Management: A Mini-review;The Open Dentistry Journal;2023-03-03